<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias </plain></SENT>
<SENT sid="1" pm="."><plain>Telomeres are thought to be critical in maintaining <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we assessed telomere dynamics in order to obtain further insight into the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We studied telomerase activity (TA) in mononuclear cells from peripheral blood (PB) and bone marrow (BM) from patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n=24), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n=14), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; n=12) and 11 <z:mpath ids='MPATH_458'>normal</z:mpath> controls using a polymerase chain reaction-based telomeric repeat amplification assay </plain></SENT>
<SENT sid="4" pm="."><plain>Telomerase activities (mean+/-S.D.) were found as 0.199+/-0.09, 0.414+/-0.55, 0.253+/-0.26 and 0.181+/-0.05 pg/ml in PB mononuclear cells, respectively (P&gt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Comparison of TA of BM mononuclear cells from 19 MDS patients versus 10 BM samples from <z:mpath ids='MPATH_458'>normal</z:mpath> controls revealed no significant difference (P=0.3) </plain></SENT>
<SENT sid="6" pm="."><plain>There was no correlation between the levels of TA and clinical and prognostic parameters of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, such as degree of <z:hpo ids='HP_0001903'>anemia</z:hpo>, platelet counts on presentation, gender, presence of organomegaly, bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> and BM blast percentages </plain></SENT>
<SENT sid="7" pm="."><plain>Patients who had higher TA had significantly inferior survival compared with patients who had lower TA (P=0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>Consistent with previous data, our results suggest that in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, telomerase activity might be insufficient to compensate for the telomere shortening </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, TA might be prognostically important in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Measurements of enzymatic activity in association with telomere length studies may help to understand the prognostic role of telomere dynamics in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> more reliably </plain></SENT>
</text></document>